Exact Mass: 505.1597
Exact Mass Matches: 505.1597
Found 268 metabolites which its exact mass value is equals to given mass value 505.1597
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
alangiside
An organic heterotetracyclic compound that is an alkaloidal glycoside isolated from Alangium salviifolium.
N-(2-Fluoro-4-(methylsulfonyl)phenyl)-6-(4-(3-isopropyl-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-5-nitropyrimidin-4-amine
Peonidin 3-(6'-acetyl-galactoside)
Peonidin 3-(6-acetyl-galactoside) is a member of the class of compounds known as anthocyanidin-3-o-glycosides. Anthocyanidin-3-o-glycosides are phenolic compounds containing one anthocyanidin moiety which is O-glycosidically linked to a carbohydrate moiety at the C3-position. Peonidin 3-(6-acetyl-galactoside) is practically insoluble (in water) and a very weakly acidic compound (based on its pKa). Peonidin 3-(6-acetyl-galactoside) can be found in highbush blueberry and lowbush blueberry, which makes peonidin 3-(6-acetyl-galactoside) a potential biomarker for the consumption of these food products.
Peonidin 3-(6'-acetyl-glucoside)
Peonidin 3-(6-acetyl-glucoside) is a member of the class of compounds known as anthocyanidin-3-o-glycosides. Anthocyanidin-3-o-glycosides are phenolic compounds containing one anthocyanidin moiety which is O-glycosidically linked to a carbohydrate moiety at the C3-position. Peonidin 3-(6-acetyl-glucoside) is practically insoluble (in water) and a very weakly acidic compound (based on its pKa). Peonidin 3-(6-acetyl-glucoside) can be found in common grape, grape wine, highbush blueberry, and lowbush blueberry, which makes peonidin 3-(6-acetyl-glucoside) a potential biomarker for the consumption of these food products.
Peonidin 3-(6-acetylglucoside)
beta-D-fructofuranosyl-(2->1)-alpha-D-[2-O-L-tyrosyl]glucopyranoside
Glu Asp Gln Asp
2-[5-chloro-7-(3,5-dihydroxyhexanoyloxy)-3-[(1E,3E,5E)-hepta-1,3,5-trienyl]-7-methyl-6,8-dioxoisoquinolin-2-yl]acetic acid
Ala Asp Asp Trp
Ala Asp Trp Asp
Ala Trp Asp Asp
Cys Asn Asn Arg
Cys Asn Arg Asn
Cys Pro Thr Trp
Cys Pro Trp Thr
Cys Gln Gln Gln
Cys Arg Asn Asn
Cys Thr Pro Trp
Cys Thr Trp Pro
Cys Trp Pro Thr
Cys Trp Thr Pro
Asp Ala Asp Trp
Asp Ala Trp Asp
Asp Asp Ala Trp
Asp Asp Glu Lys
Asp Asp Glu Gln
Asp Asp Lys Glu
Asp Asp Gln Glu
Asp Asp Trp Ala
Asp Glu Asp Lys
Asp Glu Asp Gln
Asp Glu Glu Asn
Asp Glu Gly Trp
Asp Glu Lys Asp
Asp Glu Asn Glu
Asp Glu Gln Asp
Asp Glu Trp Gly
Asp Gly Glu Trp
Asp Gly Trp Glu
Asp Lys Asp Glu
Asp Lys Glu Asp
Asp Asn Glu Glu
Asp Gln Asp Glu
Asp Gln Glu Asp
Asp Trp Ala Asp
Asp Trp Asp Ala
Asp Trp Glu Gly
Asp Trp Gly Glu
Glu Asp Asp Lys
Glu Asp Asp Gln
Glu Asp Glu Asn
Glu Asp Gly Trp
Glu Asp Lys Asp
Glu Asp Asn Glu
Glu Asp Trp Gly
Glu Glu Asp Asn
Glu Glu Asn Asp
Glu Glu Gln Thr
Glu Glu Thr Gln
Glu Gly Asp Trp
Glu Gly Trp Asp
Glu Lys Asp Asp
Glu Asn Asp Glu
Glu Asn Glu Asp
Glu Gln Asp Asp
Glu Gln Glu Thr
Glu Gln Thr Glu
Glu Thr Glu Gln
Glu Thr Gln Glu
Glu Trp Asp Gly
Glu Trp Gly Asp
Gly Asp Glu Trp
Gly Asp Trp Glu
Gly Glu Asp Trp
Gly Glu Trp Asp
Gly Trp Asp Glu
Gly Trp Glu Asp
Lys Asp Asp Glu
Lys Asp Glu Asp
Lys Glu Asp Asp
Met Met Pro Gln
Met Met Gln Pro
Met Asn Asn Gln
Met Asn Gln Asn
Met Pro Met Gln
Met Pro Gln Met
Met Gln Met Pro
Met Gln Asn Asn
Met Gln Pro Met
Asn Cys Asn Arg
Asn Cys Arg Asn
Asn Asp Glu Glu
Asn Glu Asp Glu
Asn Glu Glu Asp
Asn Met Asn Gln
Asn Met Gln Asn
Asn Asn Cys Arg
Asn Asn Met Gln
Asn Asn Gln Met
Asn Asn Arg Cys
Asn Gln Met Asn
Asn Gln Asn Met
Asn Arg Cys Asn
Asn Arg Asn Cys
Pro Cys Thr Trp
Pro Cys Trp Thr
Pro Met Met Gln
Pro Met Gln Met
Pro Gln Met Met
Pro Thr Cys Trp
Pro Thr Trp Cys
Pro Trp Cys Thr
Pro Trp Thr Cys
Gln Cys Gln Gln
Gln Asp Asp Glu
Gln Asp Glu Asp
Gln Glu Asp Asp
Gln Glu Glu Thr
Gln Glu Thr Glu
Gln Met Met Pro
Gln Met Asn Asn
Gln Met Pro Met
Gln Asn Met Asn
Gln Asn Asn Met
Gln Pro Met Met
Gln Gln Cys Gln
Gln Gln Gln Cys
Gln Thr Glu Glu
Arg Cys Asn Asn
Arg Asn Cys Asn
Arg Asn Asn Cys
Thr Cys Pro Trp
Thr Cys Trp Pro
Thr Glu Glu Gln
Thr Glu Gln Glu
Thr Pro Cys Trp
Thr Pro Trp Cys
Thr Gln Glu Glu
Thr Trp Cys Pro
Thr Trp Pro Cys
Trp Ala Asp Asp
Trp Cys Pro Thr
Trp Cys Thr Pro
Trp Asp Ala Asp
Trp Asp Asp Ala
Trp Asp Glu Gly
Trp Asp Gly Glu
Trp Glu Asp Gly
Trp Glu Gly Asp
Trp Gly Asp Glu
Trp Gly Glu Asp
Trp Pro Cys Thr
Trp Pro Thr Cys
Trp Thr Cys Pro
Trp Thr Pro Cys
4-[[5-(acetylamino)-1-methyl-1H-indol-3-yl]methyl]-3-methoxy-N-[(2-methylphenyl)sulfonyl]-Benzamide
2,2-[[3-acetamido-4-[(2-chloro-4-nitrophenyl)azo]phenyl]imino]diethyl diacetate
TERT-BUTYL ((S)-1-((S)-2-CARBAMOYLPYRROLIDIN-1-YL)-1-OXO-3-(1-TOSYL-1H-IMIDAZOL-4-YL)PROPAN-2-YL)CARBAMATE
4-Methoxyphenyl 3-O-Benzyl-2-deoxy-2-phthalimido-beta-D-glucopyranoside
9H-Carbazole, 9-[1,1-biphenyl]-4-yl-3-(4-chlorophenyl)-6-phenyl-
7-[(3S,5S)-3-amino-5-methylpiperidin-1-yl]-1-cyclopropyl-8-methoxy-4-oxoquinoline-3-carboxylic acid,2-hydroxybutanedioic acid
(S)-2-[[3,5-Bis(trifluoromethyl)phenyl]thioureido]-N-benzyl-N,3,3-trimethylbutanamide
Nefazodone hydrochloride
D018377 - Neurotransmitter Agents > D014179 - Neurotransmitter Uptake Inhibitors > D000068760 - Serotonin and Noradrenaline Reuptake Inhibitors D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D000928 - Antidepressive Agents D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D012702 - Serotonin Antagonists C78272 - Agent Affecting Nervous System > C265 - Antidepressant Agent D049990 - Membrane Transport Modulators Nefazodone hydrochloride (BMY-13754) is a potent and selective 5HT2A (Ki=5.8 nM) antagonist with moderate inhibition of 5-HT and noradrenaline uptake (IC50 of 290 and 300 nM, respectively). Nefazodone hydrochloride is a phenylpiperazine antidepressant with less alpha-adrenergic blocking activity[1][2].
4-(FMOC-2-AMINOETHYL)-6-DIBENZOFURANPROPIONIC ACID
Dasatinib hydrate
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C155700 - BCR-ABL Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor D004791 - Enzyme Inhibitors > D047428 - Protein Kinase Inhibitors D000970 - Antineoplastic Agents
4-Methylumbelliferyl2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-b-D-glucopyranoside
4-Methylumbelliferyl 2-Acetamido-2-deoxy-3,4,6-tri-O-acetyl-β-D-Galactopyranoside
Adavivint
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor D000893 - Anti-Inflammatory Agents
peonidin 3-O-(6-O-acetyl-beta-D-glucoside)
An anthocyanin cation that is peonidin substituted at position 3 by a 6-O-acetyl-beta-D-glucosyl residue.
5-chloro-2-propyl-3-[4-[4-[2-(2H-tetrazol-5-ylmethyl)phenyl]phenyl]phenyl]imidazo[4,5-b]pyridine
N-[4-[[2-methoxy-5-[4-oxo-3-(phenylmethyl)-2-quinazolinyl]phenyl]methoxy]phenyl]acetamide
(11S,12aR,13aR)-12-ethenyl-11-(beta-D-glucopyranosyloxy)-2-hydroxy-3-methoxy-5,6,12,12a,13,13a-hexahydro-11H-pyrano[4,3:4,5]pyrido[2,1-a]isoquinolin-8-one
2-[[[(2R,3S)-8-bromo-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl-methylamino]methyl]benzoic acid
2-[[[(2R,3R)-8-bromo-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl-methylamino]methyl]benzoic acid
(3S)-3-[[[(2S)-1-[(2S)-2-[[(4-amino-3-chlorophenyl)-oxomethyl]amino]-3,3-dimethyl-1-oxobutyl]-2-pyrrolidinyl]-oxomethyl]amino]-3-cyanopropanoic acid ethyl ester
3-(3-fluorophenyl)-1-[[(4S,5R)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-[(E)-prop-1-enyl]-4,5-dihydro-3H-6,1lambda6,2-benzoxathiazocin-5-yl]methyl]-1-methylurea
3-(3-fluorophenyl)-1-[[(4R,5S)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-[(E)-prop-1-enyl]-4,5-dihydro-3H-6,1lambda6,2-benzoxathiazocin-5-yl]methyl]-1-methylurea
3-[(3aS,4S,9bS)-4-(hydroxymethyl)-1-(4-methylphenyl)sulfonyl-2,3,3a,4,5,9b-hexahydropyrrolo[3,2-c]quinolin-8-yl]-N,N-dimethylbenzamide
3-[(3aS,4R,9bS)-4-(hydroxymethyl)-1-(4-methylphenyl)sulfonyl-2,3,3a,4,5,9b-hexahydropyrrolo[3,2-c]quinolin-8-yl]-N,N-dimethylbenzamide
4-[(5-acetamido-1-methylindol-3-yl)methyl]-3-methoxy-N-(2-methylphenyl)sulonylbenzamide
3-(3-fluorophenyl)-1-[[(4S,5R)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-[(E)-prop-1-enyl]-4,5-dihydro-3H-6,1lambda6,2-benzoxathiazocin-5-yl]methyl]-1-methylurea
3-(3-fluorophenyl)-1-[[(4S,5S)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-[(E)-prop-1-enyl]-4,5-dihydro-3H-6,1lambda6,2-benzoxathiazocin-5-yl]methyl]-1-methylurea
3-(3-fluorophenyl)-1-[[(4R,5R)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-[(E)-prop-1-enyl]-4,5-dihydro-3H-6,1lambda6,2-benzoxathiazocin-5-yl]methyl]-1-methylurea
2-[(1S,3R,4aS,9aR)-1-(hydroxymethyl)-6-[(1-oxo-2-pyridin-4-ylethyl)amino]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(3-fluorophenyl)methyl]acetamide
3-(3-fluorophenyl)-1-[[(4R,5S)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-[(E)-prop-1-enyl]-4,5-dihydro-3H-6,1lambda6,2-benzoxathiazocin-5-yl]methyl]-1-methylurea
3-(3-fluorophenyl)-1-[[(4R,5R)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-[(E)-prop-1-enyl]-4,5-dihydro-3H-6,1lambda6,2-benzoxathiazocin-5-yl]methyl]-1-methylurea
3-(3-fluorophenyl)-1-[[(4S,5S)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-[(E)-prop-1-enyl]-4,5-dihydro-3H-6,1lambda6,2-benzoxathiazocin-5-yl]methyl]-1-methylurea
2-[(1R,3R,4aS,9aR)-1-(hydroxymethyl)-6-[(2-pyridin-4-ylacetyl)amino]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b][1]benzofuran-3-yl]-N-[(3-fluorophenyl)methyl]acetamide
2-[(1S,3S,4aR,9aS)-1-(hydroxymethyl)-6-[(2-pyridin-4-ylacetyl)amino]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b][1]benzofuran-3-yl]-N-[(3-fluorophenyl)methyl]acetamide
3-[(3aR,4S,9bR)-4-(hydroxymethyl)-1-(4-methylphenyl)sulfonyl-2,3,3a,4,5,9b-hexahydropyrrolo[3,2-c]quinolin-8-yl]-N,N-dimethylbenzamide
[(1S)-2-[(2,5-difluorophenyl)methyl]-1-ethylsulfonyl-7-methoxy-9-methyl-1-spiro[1,3-dihydropyrido[3,4-b]indole-4,3-azetidine]yl]methanol
3-(4-fluorophenyl)-1-[[(4R,5R)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-[(E)-prop-1-enyl]-4,5-dihydro-3H-6,1lambda6,2-benzoxathiazocin-5-yl]methyl]-1-methylurea
2-[(1R,3S,4aR,9aS)-1-(hydroxymethyl)-6-[(1-oxo-2-pyridin-4-ylethyl)amino]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(3-fluorophenyl)methyl]acetamide
2-[(1R,3S,4aS,9aR)-1-(hydroxymethyl)-6-[(1-oxo-2-pyridin-4-ylethyl)amino]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(3-fluorophenyl)methyl]acetamide
3-[(3aR,4R,9bR)-4-(hydroxymethyl)-1-(4-methylphenyl)sulfonyl-2,3,3a,4,5,9b-hexahydropyrrolo[3,2-c]quinolin-8-yl]-N,N-dimethylbenzamide
[(1R)-2-[(2,5-difluorophenyl)methyl]-1-ethylsulfonyl-7-methoxy-9-methyl-1-spiro[1,3-dihydropyrido[3,4-b]indole-4,3-azetidine]yl]methanol
(E)-N-[2-(4-hydroxy-3-methoxyphenyl)ethyl]-3-[3-methoxy-4-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]prop-2-enamide
2-[5-chloro-7-(3,5-dihydroxyhexanoyloxy)-3-[(1E,3E,5E)-hepta-1,3,5-trienyl]-7-methyl-6,8-dioxoisoquinolin-2-yl]acetic acid
SRT 1720 (monohydrochloride)
SRT 1720 monohydrochloride is a selective and orally active activator of SIRT1 with an EC50 of 0.10 μM, and shows less potent activities on SIRT2 and SIRT3[1].